Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

COPD Acute Exacerbation: early-phase trial registry

1 of 1 indexed COPD Acute Exacerbation trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

COPD Acute Exacerbation: 1 US clinical trial tracked, 1 recruiting.

COPD Acute Exacerbation is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Connect Biopharm, running 1 of these trials.

Enrollment posture brief

Registry condition copd-acute-exacerbation

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

COPD Acute Exacerbation (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near COPD Acute Exacerbation

COPD Acute Exacerbation lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for COPD Acute Exacerbation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. COPD Acute Exacerbation is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Connect Biopharm 1 trials

Named interventions

Most-linked intervention names on COPD Acute Exacerbation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Matching placebo in prefilled syringe Drug
1 trials
Rademikibart in prefilled syringe Combination
1 trials

US sites by state

Facility locations filed on COPD Acute Exacerbation trials. A trial with sites in several states counts in each.

Virginia 1 trials
Texas 1 trials
South Carolina 1 trials
Ohio 1 trials
North Carolina 1 trials
Kansas 1 trials
Iowa 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this COPD Acute Exacerbation page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 COPD Acute Exacerbation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Connect Biopharm sponsors the most COPD Acute Exacerbation trials on record, review their full trial history before evaluating a specific study. See Connect Biopharm's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COPD Acute Exacerbation condition card totals 1 registered trials; most-linked intervention Matching placebo in prefilled syringe; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.